Evidence map›Paper›PMID 25559818›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

Ian J Majewski, Paolo Nuciforo, Lorenza Mittempergher, Astrid J Bosma, Holger Eidtmann, Eileen Holmes, Christos Sotiriou, Debora Fumagalli, Jose Jimenez, Claudia Aura and 11 more

Open access · bronzeAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 3 pooled it
17.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

128 citing papers in PubMed, 3 syntheses or guidelines pooled it, 224 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2017
    Trial
  14. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Review

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 3 countries.

Ian J MajewskiIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Paolo NuciforoIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Lorenza MittempergherIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Astrid J BosmaIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Holger EidtmannIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Eileen HolmesIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Christos SotiriouIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Debora FumagalliIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Jose JimenezIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Claudia AuraIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Ludmila PrudkinIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Maria Carmen Díaz-DelgadoIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Lorena de la PeñaIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Sherene LoiIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Catherine EllisIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Nikolaus SchultzIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Evandro de AzambujaIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Nadia HarbeckIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
Martine Piccart-GebhartIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
René BernardsIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.
José BaselgaIan J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY. baselgaj@mskcc.org.
Asociación Española Contra el Cáncer · ESInstitut Jules Bordet · BE

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeWe investigated whether mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) correlates with response to neoadjuvant human epidermal growth factor receptor 2 (HER2) -targeted therapies in patients with breast cancer. PATIENTS AND

methodsBaseline tissue biopsies were available from patients with HER2-positive early breast cancer who were enrolled onto the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial (NeoALTTO). Activating mutations in PIK3CA were identified using mass spectrometry-based genotyping.

resultsPIK3CA mutations were identified in 23% of HER2-positive breast tumors, and these mutations were associated with poorer outcome in all of the treatment arms. Patients treated with a combination of trastuzumab and lapatinib who had wild-type PIK3CA obtained a total pathologic complete response (pCR) rate of 53.1%, which decreased to 28.6% in patients with tumors that carried PIK3CA activating mutations (P = .012).

conclusionActivating mutations in PIK3CA predicted poor pCR in patients with HER2-positive breast cancer treated with neoadjuvant therapies that target HER2. Consequently, the combination of anti-HER2 agents and PI3K inhibitors is being investigated.

Indexed as

MutationAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantClass I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesFemaleHumansLapatinibMiddle AgedMolecular Targeted TherapyNeoadjuvant TherapyNeoplasm StagingPhosphatidylinositol 3-KinasesAntibodies, Monoclonal, HumanizedClass I Phosphatidylinositol 3-KinasesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLapatinibPhosphatidylinositol 3-KinasesPIK3CA protein, humanQuinazolinesTrastuzumab

Identifiers

PMID25559818
PMCPMC5087318
OpenAlexW2118419063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.